Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:small_molecule
gptkb:drug |
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AX12
|
| gptkbp:brand |
Xolremdi
|
| gptkbp:CASNumber |
1202237-69-0
|
| gptkbp:chemicalFormula |
C27H32N6O2
|
| gptkbp:developer |
gptkb:X4_Pharmaceuticals
|
| gptkbp:indication |
treatment of WHIM syndrome in patients aged 12 years and older
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:CXCR4_antagonist
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
CXCR4 receptor
|
| gptkbp:usedFor |
gptkb:WHIM_syndrome
|
| gptkbp:bfsParent |
gptkb:X4_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
mavorixafor
|